Bio Experts Gather in One Place... Bio Association to Host 'BIX 2023' Next Month

The Korea Bio Association and Reed Exhibitions Korea (RX) announced on the 22nd that they will host a comprehensive bio convention, "BioPlus-Interphex Korea 2023 (BIX)," by inviting bioindustry experts to one place.

[Image courtesy of Korea Bio Association]

The conference of this event, held on-site at COEX in Gangnam-gu, Seoul from the 12th to the 14th of next month, will take place in the COEX Conference Room (3rd floor) and is largely composed of keynote sessions (3) and general sessions (21).

On the first day of the event, the keynote session titled "REVAMPING THE INDUSTRY I - Current Status and Future Direction of the Korean Bio Industry" will be chaired by Lee Seung-gyu, Vice Chairman of the Korea Bio Association, who will present solutions to overcome the triple challenges faced by the bio industry, including high exchange rates, weakened investment sentiment, and raised listing hurdles.

In the following specialized sessions, discussions will focus on platform technologies, which are crucial material delivery technologies to enhance drug delivery efficacy, the business feasibility of combination therapies, and the potential entry into the global public health procurement market. Essential topics in the bio industry such as cold chain logistics, global clinical trials, and the U.S. Food and Drug Administration (FDA)'s DHT (Digital Health Technologies) program will also be spotlighted.

The keynote session on the second day will address the Latin American market, where recent advances by domestic pharmaceutical and bio companies have been ongoing. Under the theme "Current Status of the Latin American Pharmaceutical and Bio Market - Focusing on Brazil's Public Health Procurement Market," the session will examine key issues in Brazil, a core Latin American country, to understand the Latin American public health procurement market. Additionally, sessions such as "Biden Executive Order, Impact on the Korean Bioeconomy, and BioUSA 2023 Debriefing," which interprets the impact of the U.S. Biden administration's executive order on the Korean bioindustry from an American perspective, and "Doctors Speak: What Criteria Do I Use for Prescriptions?" featuring practicing physicians, will be held. Other sessions will cover topics like microbiome therapeutics and dementia treatments.

On the final third day, the voices of young bio entrepreneurs will be heard. The keynote session "REVAMPING THE INDUSTRY II - 90s-born CEOs Leading the Future" will introduce the management philosophies and leadership of CEOs born in the 1990s, known as the MZ generation (Millennials + Generation Z), through their startup stories, and collectively envision future models for bio companies.

Moreover, in "New Drug Development and Partnering in the Digital Era," the U.S. law firm Sidley will introduce the FDA's latest initiative on product development related to digital health technologies, the DHT (Digital Health Technologies) program, and explain how our research and development (R&D) companies can advantageously utilize incentives under the Inflation Reduction Act (IRA). Discussions will also cover the latest trends in cell and gene therapies (CGT) and delivery technologies, as well as workforce issues.

Meanwhile, in addition to keynote and specialized sessions, BIX will also feature major side events such as sponsor company sessions and corporate presentations. Key event information can be found on the BIX event secretariat's website.

This content was produced with the assistance of AI translation services.